GenScript Sets Up State-Of-Art Manufacturing Facility in Singapore to Strengthen Manufacturing Capability

SINGAPORE,Feb. 10,2022 -- GenScript Biotech Corporation (Stock Code: 1548.HK),the world's leading life science research tools and services provider,today announced the opening of more than 30,000-square-feet facility for highly automated protein and gene preparation services. The state-of-the-art site marks a significant expansion of the company's advanced protein and gene platforms,and is designed to provide high quality,fast-turnaround on products required for new vaccines and therapeutics development and innovations in life sciences. Supported by the Singapore's Economic Development Board (EDB),the new production site will support the Asia Pacific region and complements the current production sites in the United States and China.

Automated liquid handling system to support high throughput protein production

Virtual ribbon cutting ceremony

The opening ceremony was held on a virtual setting inaugurated by Minister of State for Trade and Industry,and Culture,Community and Youth,Mr Alvin Tan and accompanied by Senior Vice President and Head,Healthcare,Singapore Economic Development Board (EDB),Ms Goh Wan Yee. During the ceremony,GenScript and Diagnostics Development (DxD) Hub,a national platform hosted by the Agency for Science,Technology and Research (A*STAR),signed a memorandum of understanding (MoU) to explore collaborations to build manufacturing capabilities in Singapore.

The new manufacturing facility occupies over 30,000 square feet space at Solaris@Kallang building. The cutting edge facility in Singapore features a high throughput platform and proprietary technology of GenScript's protein production to provide higher yield with a shorter turnaround time. Together with an experienced scientific and commercial team,GenScript is committed to providing tailored and top notch service to the region. The capacity of the new facility could also be expanded to strengthen other business units to support cell and gene therapy and vaccine development in the region.

"This is a significant milestone for us as we strengthen our presence in the vibrant and innovative ecosystem in Asia Pacific,Singapore. The new manufacturing facility will be a regional innovation and excellence hub in Asia Pacific and increase productivity of custom protein manufacturing," said Mr. Johnson Wang,President of GenScript Asia Pacific Division. "With the new manufacturing plant,we will be able to foster stronger collaboration with partners,research institutes and biopharmaceutical companies across the Asia Pacific region."

"Singapore the home to GenScript's Asia Pacific headquarters,it is also a strategic location for us to expand our manufacturing capability to support the fast growing biotechnology industry. With the strong support from EDB,our new facility aims to be the center of a solid regional network to catalyze more collaboration,ultimately spurring more innovation and breakthrough life science. This demonstrated GenScript's commitment to building and developing the world leading enabling platform in serving science," said Dr. Ray Chen,President of Life Science Group,GenScript Biotech Corporation.

"GenScript's decision to set up its new production site and business hub in Singapore is testament to our robust manufacturing infrastructure,R&D and innovation ecosystem,strong base of biotech talent,as well as our excellent connectivity to the Asia-Pacific region. We look forward to working closely with GenScript to further expand its regional footprint,nurture local talent and drive better healthcare outcomes," said Ms Goh Wan Yee,Senior Vice President and Head,EDB.

About GenScript Biotech Corporation

GenScript Biotech Corporation (Stock Code: 1548.HK) is the world's leading technology and service provider of life science R&D and manufacture. Built upon its solid gene synthesis technology,GenScript Biotech is divided into four major platforms including the life science service and product platform,the biologics contract development and manufacturing organization (CDMO) platform,the global cell therapy platform and the industrial synthesis biological product platform.

GenScript Biotech was founded in New Jersey,US in 2002 and listed on the Hong Kong Stock Exchange in 2015. GenScript Biotech's business operations span over 100 countries and regions worldwide with legal entities located in the US,Mainland China,Hong Kong,China,Japan,Singapore,the Netherlands and Ireland. GenScript Biotech provides premium,convenient and reliable services and products for over 100,000 customers.

As of June 30,2021,GenScript Biotech had more than 4500 employees globally,over 40% of whom hold master's and/or Ph.D. degrees. In addition,GenScript Biotech owns a number of intellectual property rights,including over 160 patents,over 600 pending patent applications and great numbers of trade secrets.

Driven by the corporate mission of "making people and nature healthier through biotechnology",GenScript Biotech strives to become the most trustworthy biotech company in the world. As of June 30,GenScript Biotech's services and products have been cited by 64,700 peer-reviewed journal articles worldwide.

For more information,please visit GenScript Biotech's official website

https://www.genscript.com